Innovation | Novartis

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.

InnovationFuture of HealthcareDrug Development
From Our Labs

When it comes to cancer, there’s power in a good partner

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

CancerClinical ResearchInnovationOncologyScientific Research
Discovery

Solving the puzzle of immunotherapy

From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.

CancerInnovationScientific ResearchOncology
Access to Healthcare

To make a difference, start with patients

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Drug DevelopmentInnovationWorking at Novartis
Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz

Annonce événementielle selon l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosis

Basel, June 22, 2021 — Today, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab) over 3.5 years. The ongoing open label extension of the ALITHIOS study includes 1,703 people living with MS taking Kesimpta for up to 5 years. At the time…

NeuroscienceInnovation
Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineInnovationAd Hoc
Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées

Annonce événementielle selon l’art. 53 RC

Reimagine MedicineInnovationAd Hoc
Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineInnovationAd Hoc
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Basel, September 8, 2020 — Novartis announced today it will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.

Reimagine MedicineNeuroscienceInnovation